CommercialCoverageMedium impact
07.05.06h, Transcatheter Arterial Chemoembolization (TACE) of Hepatic Malignancies
Independence Blue Cross·Oncology, Radiology, Radiation Oncology·Medical Policy
Effective date
Mar 5, 2025
We identified it
Jun 19, 2026
Summary
Policy 07.05.06h regarding Transcatheter Arterial Chemoembolization (TACE) for hepatic malignancies has been reissued effective March 5, 2025. The billing team must review this reissued policy to identify any changes to coverage criteria, billing codes, prior authorization requirements, or documentation standards that may affect claim submission and reimbursement for TACE procedures.
Action Required
By March 5, 2025: Billing team must obtain and review the complete policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=03&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-07-05-06h. Identify specific changes from the prior version, including: (1) any new or modified CPT/HCPCS codes for TACE procedures, (2) updated prior authorization requirements, (3) revised medical necessity documentation standards, and (4) coverage limitations by diagnosis or patient population. Update billing system rules, encounter forms, and provider education materials accordingly. Flag any claims submitted between the old and new effective dates for potential rebilling if coverage criteria changed.